ReviewBioMed research international2021
COVID-19 Vaccine, TRIPS, and Global Health Diplomacy: India's Role at the WTO Platform.
Review in BioMed research international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it.
- On the momentum toward vaccine self-sufficiency in the BRICS: an integrative review of the role of pharmaceutical entrepreneurship and innovation.Frontiers in public health · 2023Pooled it
- Decolonizing global health in an age of fragmentation: reimagining equity for universal health coverage.Health policy and planning · 2026Article
- Shifting power dynamics in global health governance: a challenge and an opportunity for Asia and the Global South.BMJ global health · 2025Article
- Bridging international borders through global health diplomacy: A comprehensive bibliometric analysis of the state of play and leads for advancing this domain.Health promotion perspectives · 2025Review
- States, global power and access to medicines: a comparative case study of China, India and the United States, 2000-2019.Globalization and health · 2025Article
- Article
- Health technology assessment for digital health Technologies in India: a framework for action.International journal of technology assessment in health care · 2024Article
- Pandemic treaty as an instrument to strengthen global health security: Global health diplomacy at its crux.Health promotion perspectives · 2024Review
- Political Prioritization of Access to Medicines and Right to Health: Need for an Effective Global Health Governance Through Global Health Diplomacy Comment on "More Pain, More Gain! The Delivery of COVID-19 Vaccines and the Pharmaceutical Industry's Role in Widening the Access Gap".International journal of health policy and management · 2024Article
- Addressing Chronic Conditions and Social Determinants of Health During the COVID-19 Pandemic.Advances in experimental medicine and biology · 2024Article
- Designing the global vaccine supply chain: balancing intellectual property rights with post COVID-19 vaccine equity.BMJ global health · 2023Review
- Article
- COVID-19 and Global Distributive Justice: 'Health Diplomacy' of India and South Africa for the TRIPS waiver.Journal of Asian and African studies · 2023Article
- Reimagining diaspora diplomacy during the COVID-19 crisis in India.International health · 2023Article
- Editorial: Global excellence in health economics: Asia and Australasia.Frontiers in public health · 2023Article
- Access to medicines through global health diplomacy.Health promotion perspectives · 2023Review
- The rise of India's global health diplomacy amid COVID-19 pandemic.Health promotion perspectives · 2023Article
- Editorial: Role of health economic data in policy making and reimbursement of new medical technologies, Volume II.Frontiers in public health · 2023Article
- Impact of good governance, economic growth and universal health coverage on COVID-19 infection and case fatality rates in Africa.Health research policy and systems · 2022Article
- Pandemic preparedness and response: exploring the role of universal health coverage within the global health security architecture.The Lancet. Global health · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In light of the devastation caused by COVID-19, the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) and vaccine research and development (R&D) have been occupying a prominent position in the field of global health diplomacy (GHD). Most countries, international organizations, and charitable organizations have been engaged in the R&D of COVID-19 vaccines to ensure timely affordability and accessibility to all countries. Concomitantly, the World Trade Organization (WTO) provides some provisions and enforcements regarding copyrights, patents, trademarks, geographical indications, and industrial designs. Given these safeguards, it is considered that intellectual property rights (IPRs) have become major barriers to the affordability and accessibility of vaccines/medicines/technology, particularly to the developing/least developed countries. Realizing the gravity of the pandemic impact, as well as its huge population and size, India has elevated this issue in its global health diplomacy by submitting a joint proposal with South Africa to the World Trade Organization (WTO) for a temporary waiver of IPRs to ensure timely affordability and accessibility of COVID-19 medical products to all countries. However, the issue of the temporary waive off had become a geopolitical issue. Countries that used to claim per se as strong advocates of human rights, egalitarianism, and healthy democracy have opposed this proposal. In this contrasting milieu, this paper is aimed at examining how the TRIPS has become a barrier for developing countries' development and distribution of vaccines/technology; secondly, how India strategizes its role in the WTO in pursuant of its global health diplomacy? We conclude that the IPRs regime should not become a barrier to the accessibility/affordability of essential drugs and vaccines. To ensure access, India needs to get more engaged in GHD with all the involved global stakeholders to get strong support for their joint proposal. The developed countries that rejected/resisted the proposal can rethink their full support.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.